Heading 6

Biogenes signs exclusive licensing agreement with IUKL

BANGI: Bioegenes Technologies Sdn Bhd (Biogenes), a Malaysian-based company in the field of molecular diagnostics and genomics has signed a licensing agreement with Infrastructure University Kuala Lumpur (IUKL) to commercialise Aptamer technology.

Antibodies, aptamer & a kinder approach

The very nature of our technology helps you go outside and try it in the field. 

Collaborating genomic tech for precision breeding

Monash University Malaysia and Biogenes Technologies Sdn Bhd signed a Memorandum of Agreement (MoA) on collaborative research to develop genomic technologies.

M’sian made aptamer-based biosensor makes its mark

A locally developed aptamer-based biosensor is set to change the way we monitor human body, pathogens, food and environmental contaminants.

AIM Ambil Pendekatan Inovatif Perangi Covid-19 

Agensi Inovasi Malaysia (AIM) melalui empat syarikat Program Berimpak Tinggi 2 (HIP2) di bawah PlaTCOM Ventures Sdn Bhd dan sebuah syarikat pelaburan mengambil pendekatan inovatif untuk memerangi koronavirus (Covid-19) dengan menghasilkan produk perubatan dan klinikal selain memulakan penyelidikan vaksin.

Syarikat tersebut ialah Twin Catalyst Sdn Bhd, TTMC Sdn Bhd, Medical Innovation Ventures Sdn Bhd (Mediven), Biogenes Technologies Sdn Bhd dan IN3Bio.

15 Startups graduated from Antler's fourth Singapore cohort and COVID-19 Initiative

Bio Genes: A startup that produces aptamer-based (synthetic antibody) diagnostics products via an in-house proprietary technology platform.

15 new startups that have received funding from Antler

Global startup generator and early-stage VC firm Antler has announced the 15 new companies that have graduated and received investment from its fourth Singapore programme.

Malaysian companies develop Covid-19 rapid test kits

Homegrown technology company Biogenes Technologies Sdn Bhd is developing an aptamer-based biosensor against the novel coronavirus that can accurately deliver test results in under one minute. 

BH covid 19.webp

COVID-19: Syarikat naungan AIM hasil vaksin, kit ujian

KUALA LUMPUR: Lima syarikat kini dalam pelbagai fasa bagi mengetengahkan produk perubatan untuk pengesanan virus dan klinikal, selain merintis usaha penyelidikan vaksin COVID-19.

 

Syarikat itu merangkumi Twin Catalyst Sdn Bhd, TTMC Sdn Bhd, Medical Innovation Ventures Sdn Bhd (Mediven), Biogenes Technologies Sdn Bhd dan IN3Bio.